

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the prospectus dated December 12, 2025 (the “**Prospectus**”) of BenQ BM Holding Cayman Corp. (明基醫院集團股份有限公司) (the “**Company**”).

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities. This announcement is not a prospectus. Potential investors should read the Prospectus for detailed information about the Global Offering described below before deciding whether or not to invest in the Offer Shares. Any investment decision in relation to the Offer Shares should be taken solely in reliance on the information provided in the Prospectus.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States or in any other jurisdictions. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933 as amended from time to time (the “**U.S. Securities Act**”) or securities law of any state or other jurisdiction of the United States. The securities may not be offered, sold, pledged, or transferred within the United States or to, or for the account or benefit of U.S. persons (as defined in Regulation S under the U.S. Securities Act (“**Regulation S**”)) except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and in compliance with any applicable state securities laws. There will be no public offering of securities in the United States. The Offer Shares are being offered and sold outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act.

No stabilizing manager will be appointed, and it is anticipated that no stabilization activities will be carried out in relation to the Global Offering.

The Hong Kong Offer Shares will be offered to the public in Hong Kong subject to term and conditions set out in the Prospectus. Potential investors of the Offer Shares should note that the Overall Coordinators (for themselves and on behalf of the Hong Kong Underwriters) shall be entitled to terminate the Hong Kong Underwriting Agreement with immediate effect upon the occurrence of any of the events set out in the section headed “Underwriting — Underwriting Arrangements and Expenses — Hong Kong Public Offering — Hong Kong Underwriting Agreement — Grounds for Termination” in the Prospectus at any time prior to 8:00 a.m. on the Listing Date.



BenQ BM Holding Cayman Corp.
明基醫院集團股份有限公司

(A company incorporated in the Cayman Islands with limited liability)

GLOBAL OFFERING

Number of Offer Shares under the Global Offering	: 67,000,000 Offer Shares
Number of Hong Kong Offer Shares	: 6,700,000 Offer Shares (subject to reallocation)
Number of International Offer Shares	: 60,300,000 Offer Shares (subject to reallocation)
Maximum Offer Price	: HK\$11.68 per Offer Share plus brokerage of 1%, SFC transaction levy of 0.0027%, AFRC transaction levy of 0.00015% and Stock Exchange trading fee of 0.00565% (payable in full on application in Hong Kong dollars, subject to refund)
Nominal value	: US\$1.00 per Share
Stock code	: 2581

*Joint Sponsors, Overall Coordinators, Joint Global Coordinators,
Joint Bookrunners and Joint Lead Managers*



Joint Global Coordinator, Joint Bookrunner and Joint Lead Manager



CTBC BANK
中國信託銀行

Joint Bookrunners and Joint Lead Managers



**IMPORTANT NOTICE TO INVESTORS:
FULLY ELECTRONIC APPLICATION PROCESS**

We have adopted a fully electronic application process for the Hong Kong Public Offering. We will not provide printed copies of the prospectus to the public in relation to the Hong Kong Public Offering.

The prospectus is available at the website of the Stock Exchange at www.hkexnews.hk under the “*HKEXnews > New Listings > New Listing Information*” section, and our website at www.benqmedicalcenter.com. If you require a printed copy of the prospectus, you may download and print from the website addresses above.

To apply for the Hong Kong Offer Shares, you may:

- (1) apply online through the **White Form eIPO** service at www.eipo.com.hk; or
- (2) apply electronically through the **HKSCC EIPO** channel and cause HKSCC Nominees to apply on your behalf by instructing your broker or custodian who is a HKSCC Participant to give **electronic application instructions** via HKSCC’s FINI system to apply for the Hong Kong Offer Shares on your behalf.

We will not provide any physical channels to accept any application for the Hong Kong Offer Shares by the public. The contents of the electronic version of the prospectus are identical to the printed prospectus as registered with the Registrar of Companies in Hong Kong pursuant to Section 342C of the Companies (Winding Up and Miscellaneous Provisions) Ordinance.

If you are an *intermediary, broker or agent*, please remind your customers, clients or principals, as applicable, that the prospectus is available online at the website addresses above.

Please refer to “How to Apply for Hong Kong Offer Shares” in the prospectus for further details on the procedures through which you can apply for the Hong Kong Offer Shares electronically.

Your application through the **White Form eIPO** service or the **HKSCC EIPO** channel must be for a minimum of 500 Hong Kong Offer Shares and in one of the numbers set out in the table below.

If you are applying through the **White Form eIPO** service, you may refer to the table above for the amount payable for the number of Shares you have selected. You must pay the respective amount payable on application in full upon application for Hong Kong Offer Shares.

If you are applying through the **HKSCC EIPO** channel, your **broker** or **custodian** may require you to pre-fund your application in such amount as determined by the broker or custodian, based on the applicable laws and regulations in Hong Kong. You are responsible for complying with any such pre-funding requirement imposed by your broker or custodian with respect to the Hong Kong Offer Shares you applied for.

No. of Hong Kong Offer Shares applied for	Amount payable ⁽²⁾ on application	No. of Hong Kong Offer Shares applied for	Amount payable ⁽²⁾ on application	No. of Hong Kong Offer Shares applied for	Amount payable ⁽²⁾ on application	No. of Hong Kong Offer Shares applied for	Amount payable ⁽²⁾ on application
	HK\$		HK\$		HK\$		HK\$
500	5,898.90	7,000	82,584.55	50,000	589,889.65	700,000	8,258,454.95
1,000	11,797.80	8,000	94,382.34	60,000	707,867.57	800,000	9,438,234.25
1,500	17,696.69	9,000	106,180.14	70,000	825,845.50	900,000	10,618,013.52
2,000	23,595.59	10,000	117,977.93	80,000	943,823.42	1,000,000	11,797,792.80
2,500	29,494.48	15,000	176,966.89	90,000	1,061,801.35	1,500,000	17,696,689.20
3,000	35,393.38	20,000	235,955.86	100,000	1,179,779.28	2,000,000	23,595,585.60
3,500	41,292.27	25,000	294,944.82	200,000	2,359,558.55	2,500,000	29,494,482.00
4,000	47,191.17	30,000	353,933.79	300,000	3,539,337.85	3,350,000 ⁽¹⁾	39,522,605.88
4,500	53,090.07	35,000	412,922.75	400,000	4,719,117.12		
5,000	58,988.97	40,000	471,911.71	500,000	5,898,896.40		
6,000	70,786.76	45,000	530,900.68	600,000	7,078,675.68		

(1) Maximum number of Hong Kong Offer Shares you may apply for.

(2) The amount payable is inclusive of brokerage, SFC transaction levy, the Stock Exchange trading fee and AFRC transaction levy. If your application is successful, brokerage will be paid to the Exchange Participants (as defined in the Listing Rules) and the SFC transaction levy, the Stock Exchange trading fee and AFRC transaction levy are paid to the Stock Exchange (in the case of the SFC transaction levy, collected by the Stock Exchange on behalf of the SFC; and in the case of the AFRC transaction levy, collected by the Stock Exchange on behalf of the AFRC).

No application for any other number of the Hong Kong Offer Shares will be considered and any such application is liable to be rejected.

APPLICATION FOR LISTING ON THE STOCK EXCHANGE

The Company has applied to the Stock Exchange for the granting of the listing of, and permission to deal in, our Shares in issue prior to the Global Offering, may be issued pursuant to all options granted under the Pre-IPO Share Option Plan and to be issued pursuant to the Global Offering. Assuming that the Hong Kong Public Offering becomes unconditional at or before 8:00 a.m. in Hong Kong on Monday, December 22, 2025, dealing in the Shares on the Stock Exchange are expected to commence at 9:00 a.m. on Monday, December 22, 2025.

STRUCTURE OF THE GLOBAL OFFERING

The Global Offering comprises:

- the Hong Kong Public Offering of initially 6,700,000 Shares (subject to reallocation), representing approximately 10.0% of the total number of Offer Shares initially available under the Global Offering, and
- the International Offering of initially 60,300,000 Shares (subject to reallocation), representing approximately 90.0% of the total number of Offer Shares initially available under the Global Offering.

The allocation of the Offer Shares between the Hong Kong Public Offering and the International Offering will be subject to reallocation as described in the section headed “Structure of the Global Offering” in the Prospectus.

The Overall Coordinators may in their discretion reallocate Offer Shares from the International Offering to the Hong Kong Public Offering to satisfy valid applications under the Hong Kong Public Offering under the condition that (a) the International Offer Shares are fully subscribed or oversubscribed and the Hong Kong Offer Shares are fully subscribed or oversubscribed irrespective of the number of times; or (b) the International Offer Shares are undersubscribed and the Hong Kong Offer Shares are fully subscribed or oversubscribed irrespective of the number of times, and up to 3,350,000 Offer Shares may be reallocated from the International Offering to the Hong Kong Public Offering, so that the total number of Offer Shares available for subscription under the Hong Kong Public Offering will increase up to 10,050,000 Offer Shares, representing approximately 15% of the number of Offer Shares initially available under the Global Offering and the final Offer Price should be fixed at the low end of the indicative Offer Price range (that is, HK\$9.34 per Offer Share) stated in the prospectus in accordance with Chapter 4.14 of the Guide for New Listing Applicants.

PRICING

The Offer Price will be no more than HK\$11.68 per Offer Share and is expected to be no less than HK\$9.34 per Offer Share unless to be otherwise announced. Applicants for the Hong Kong Offer Shares are required to pay, on application (subject to application channel), the maximum Offer Price of HK\$11.68 per Offer Share together with brokerage of 1.0%, SFC transaction levy of 0.0027%, AFRC transaction levy of 0.00015% and Stock Exchange trading fee of 0.00565%, subject to refund (subject to application channels) if the Offer Price as finally determined is less than HK\$11.68 per Offer Share.

EXPECTED TIMETABLE

Hong Kong Public Offering commences9:00 a.m. on
Friday, December 12, 2025

Latest time for completing electronic applications
under the **White Form eIPO** service through
the designated website at www.eipo.com.hk11:30 a.m. on
Wednesday, December 17, 2025

Application lists open11:45 a.m. on
Wednesday, December 17, 2025

Latest time for completing payment of **White
Form eIPO** applications by effecting internet
banking transfer(s) or PPS payment transfer(s)
and giving **electronic application instructions**
to HKSCC12:00 noon on
Wednesday, December 17, 2025

If you are instructing your **broker** or **custodian** who is a HKSCC Participant to give **electronic application instructions** via FINI in accordance with your instruction to apply for the Hong Kong Offer Shares, you are advised to contact your **broker** or **custodian** for the latest time for giving such instructions which may be different from the latest time as stated above.

Application lists close12:00 noon on
Wednesday, December 17, 2025

Expected Price Determination Date. by 12:00 noon on
Thursday, December 18, 2025

Announcement of the final Offer Price, the level
of indications of interest in the International
Offering, the level of applications in the Hong
Kong Public Offering and the basis of allocation
of the Hong Kong Offer Shares to be published
on the website of the Stock Exchange at
www.hkexnews.hk and on the website of
our Company at www.benqmedicalcenter.com
on or before.11:00 p.m., Friday, December 19, 2025

The results of allocations in the Hong Kong Public Offering (with successful applicants' identification document numbers, where appropriate) to be available through a variety of channels, including:

- in the announcement to be posted on the website of the Stock Exchange at www.hkexnews.hk and on the website of our Company at www.benqmedicalcenter.com no later than 11:00 p.m. on Friday, December 19, 2025
- from the designated results of allocations website at www.iporeresults.com.hk (alternatively: www.eipo.com.hk/eIPOAllotment) with a "search by ID" function from 11:00 p.m. on Friday, December 19, 2025 to 12:00 midnight on Thursday, December 25, 2025
- from the allocation results telephone enquiry line by calling +852 2862 8555 between 9:00 a.m. and 6:00 p.m. on Monday, December 22, 2025, Tuesday, December 23, 2025, Wednesday, December 24, 2025 and Monday, December 29, 2025

Share certificates in respect of wholly or partially successful applications to be dispatched or deposited into CCASS on or before Friday, December 19, 2025

White Form e-Refund payment instructions/refund checks in respect of wholly or partially successful applications (if applicable) or unsuccessful applications to be dispatched/collected on or before Monday, December 22, 2025

Dealings in the Shares on the Stock Exchange expected to commence at 9:00 a.m. on Monday, December 22, 2025

Note: All dates and times refer to Hong Kong local date and time, except as otherwise stated.

SETTLEMENT

Subject to the granting of listing of, and permission to deal in, the Shares on the Stock Exchange and compliance with the stock admission requirements of HKSCC, the Shares will be accepted as eligible securities by HKSCC for deposit, clearance and settlement in CCASS with effect from the date of commencement of dealings in the Shares on the Stock Exchange or any other date as determined by HKSCC. Settlement of transactions between participants of the Stock Exchange is required to take place in CCASS on the second settlement day after any trading day. All activities under CCASS are subject to the General Rules of HKSCC and the HKSCC Operational Procedures in effect from time to time. All necessary arrangements have been made enabling the Shares to be admitted into CCASS. Investors should seek the advice of their stockbroker or other professional advisers for the details of the settlement arrangements as such arrangements may affect their rights and interests.

ELECTRONIC APPLICATION CHANNELS

The Hong Kong Public Offering period will begin at 9:00 am on Friday, December 12, 2025 and end at 12:00 noon on Wednesday, December 17, 2025 (Hong Kong time).

To apply for Hong Kong Offer Shares, you may use one of the following application channels:

Application Channel	Platform	Target Investors	Application Time
White Form eIPO Service	Website: www.eipo.com.hk	Applicants who would like to receive a physical Share certificate. Hong Kong Offer Shares successfully applied for will be allotted and issued in your own name.	From 9:00 am on Friday, December 12, 2025 to 11:30 a.m. on Wednesday, December 17, 2025, Hong Kong time. The latest time for completing full payment of application monies will be 12:00 noon on Wednesday, December 17, 2025, Hong Kong time.
HKSCC EIPO channel	Your broker or custodian who is a HKSCC Participant will submit electronic application instruction(s) on your behalf through HKSCC's FINI system in accordance with your instruction	Applicants who would <u>not</u> like to receive a physical Share certificate. Hong Kong Offer Shares successfully applied for will be allotted and issued in the name of HKSCC Nominees, deposited directly into CCASS and credited to your designated HKSCC Participant's stock account.	Contact your broker or custodian for the earliest and latest time for giving such instructions, as this may vary by broker or custodian .

The **White Form eIPO** service and the **HKSCC EIPO** channel are facilities subject to capacity limitations and potential service interruptions and you are advised not to wait until the last day of the application period to apply for Hong Kong Offer Shares.

Please refer to the sections headed “Structure of the Global Offering” and “How to Apply for Hong Kong Offer Shares” of the Prospectus for details of the conditions and procedures of the Hong Kong Public Offering.

Application for the Hong Kong Offer Shares will only be considered on the basis of the terms and conditions set out in the Prospectus and the designated website (www.eipo.com.hk) for the White Form eIPO service.

PUBLICATION OF RESULTS

The Company expects to announce the results of the final Offer Price, the level of indications of interest in the International Offering, the level of applications in the Hong Kong Public Offering and the basis of allocations of Hong Kong Offer Shares on the Stock Exchange’s website at www.hkexnews.hk and the Company’s website at www.benqmedicalcenter.com by no later than 11:00 p.m. on Friday, December 19, 2025 (Hong Kong time).

The results of allocations and the identification document numbers of successful applicants (where applicable) under the Hong Kong Public Offering will be available through a variety of channels at the times and date and in the manner specified in the section headed “How to Apply for Hong Kong Offer Shares — B. Publication of Results” in the Prospectus.

If an application is rejected, not accepted or accepted in part only, or if the conditions of the Global Offering are not fulfilled in accordance with “Structure of the Global Offering — Conditions of the Global Offering” in the Prospectus or if any application is revoked, the application monies, or the appropriate portion thereof, together with the related brokerage, SFC transaction levy, AFRC transaction levy and Stock Exchange trading fee, will be refunded without interest.

No temporary document of title will be issued in respect of the Shares. No receipt will be issued for sums paid on application. Share certificates will only become valid evidence of title at 8:00 a.m. on Monday, December 22, 2025 (Hong Kong time), provided that the Global Offering has become unconditional and the right of termination described in the section headed “Underwriting” has not been exercised. Investors who trade Shares prior to the receipt of Share certificates or the Share certificates becoming valid do so entirely at their own risk.

Assuming that the Hong Kong Public Offering becomes unconditional at or before 8:00 a.m. in Hong Kong on Monday, December 22, 2025, it is expected that dealings in the Shares on the Hong Kong Stock Exchange will commence at 9:00 a.m. on Monday, December 22, 2025. The Shares will be traded on the Main Board of the Hong Kong Stock Exchange in board lots of 500 Shares each. The stock code of the Shares will be 2581.

This announcement is available for viewing on the website of the Company at www.benqmedicalcenter.com and the website of the Stock Exchange at www.hkexnews.hk.

By order of the Board
BenQ BM Holding Cayman Corp.
HSIAO Tze-Jung
Executive Director

Hong Kong, December 12, 2025

As of the date of this announcement, directors and proposed directors of the Company comprise: (i) Mr. HSIAO Tze-Jung as an executive director; (ii) Mr. CHEN Chi-Hong, Ms. HUNG Chiu-Chin, Dr. WANG Liming as non-executive directors and (iii) Dr. CHOW Hsing-Yi, Mr. WANG Wen-Tsung and Mr. CHEN Ray-Jade as independent non-executive directors.